SCHEMBL20100917

SCHEMBL20100917

CC(C)c1ccc2nc(-c3ccc4ccc(C(C)C)nc4c3)ccc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
RAB9A P51151 7/20 0.38
NPC1 O15118 6/20 0.38
SMN1; SMN2 Q16637 5/20 0.38
KDM4E B2RXH2 5/20 0.38
ALDH1A1 P00352 5/20 0.38
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
AAK1 Q2M2I8 1/20 0.36
MAPT P10636 6/20 0.36
TP53 P04637 2/20 0.36
HSD17B10 Q99714 2/20 0.36
GMNN O75496 1/20 0.36
CYP3A4 P08684 1/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.36
THPO P40225 1/20 0.36
BLM P54132 1/20 0.36
PMP22 Q01453 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21037203 0.93 RAB9A (0.38) ESR1ESR2RAB9ANPC1SMN1; SMN2
SCHEMBL889349 0.84 NPC1 (0.43) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL10118808 0.83 ESR1 (0.51) ESR1ESR2RAB9ANPC1SMN1; SMN2
SCHEMBL18760590 0.83 CYP1A2 (0.41) ESR1ESR2RAB9ANPC1SMN1; SMN2
SCHEMBL21250489 0.80 AAK1 (0.39) ESR1ESR2RAB9ANPC1SMN1; SMN2
SCHEMBL10199294 0.79 NPC1 (0.41) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL10120019 0.79 AAK1 (0.50) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL21036863 0.76 PIK3CD (0.40) ESR2RAB9ANPC1KDM4EALDH1A1
SCHEMBL24795838 0.76 ESR1 (0.40) ESR1ESR2RAB9ANPC1SMN1; SMN2
SCHEMBL30685546 0.76 ESR1 (0.40) ESR1ESR2RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10034879-B2 Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation GLOBAL BLOOD THERAPEUTICS, INC. (US) 2018-07-31 US disclosed
US-20180117040-A1 SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION GLOBAL BLOOD THERAPEUTICS, INC. 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10034879-B2 Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation HBB, HBG2, MB ESR1 3153/4885ESR2 1105/4885RAB9A 4560/4885
US-20180117040-A1 SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION HBB, HBG2, MB ESR1 3153/4885ESR2 1105/4885RAB9A 4560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.